Current stage: Exit


Creoptix founded in 2009 is based in Wädenswil, Switzerland. The company is specialized in optical instruments and consumables for the label-free analysis of molecular interactions at best-in-class sensitivity for life science research and the drug discovery industry. Creoptix is revolutionizing the study of label-free molecular interactions and changing the world of drug discovery.


Creoptix launches new way of measuring kinetics to accelerate drug discovery

February 2nd, 2021|

Creoptix, a Switzerland-based company focused on next-generation bioanalytical instruments, has launched waveRAPID (Repeated Analyte Pulses of Increasing Duration), a novel, label-free kinetic measurement method that is said to be faster than traditional kinetics.

Swiss start-ups drive research around Covid-19

May 27th, 2020|

Swiss start-ups are very active in the quest for therapies against Covid-19. You can find several examples in our article from 5 May. According to the weekly updated view of the Covid-19 product pipeline creates by BIO’a Industry Analysis Team, Swiss companies run 25 different therapeutic programmes - more than companies from UK (22), Germany (21) or France (12).

Creoptix appoints Line Stigen Raquet as CEO

December 13th, 2019|

Creoptix AG, a Switzerland-based company focused on next-generation bioanalytical instruments, today announced the appointment of Line Stigen Raquet as Chief Executive Officer with effect from beginning of January 2020. After seven years in the position, Matyas Vegh has decided to pursue new opportunities outside the company.

Go to Top